Transplantation of Genetically Engineered Cardiac Fibroblasts Producing Recombinant Human Erythropoietin to Repair the Infarcted Myocardium - Genetic Engineering: Recent Developments in Applications - page 199

study. Rats were randomized into three treatment groups (n = 15 in each group):
transduced rhEPO-producing cells, non-transduced cells, and saline injection.
Ten animals from each group (five additional animals in each group were sacri-
ficed one month after transplantation for immunohistochemical examination)
were assessed with echocardiography.
Serial echocardiography tests showed that EPO-transduced and non-trans-
duced cell injection did not reduce LV remodeling and dysfunction 5 and 9 weeks
post MI (Table 3). At 5 weeks, there was a trend towards more scar thinning in the
EPO-treated group (anterior wall diastolic thickness, p = 0.07; LV end diastolic
dimension, p = 0.08).
Table 3. Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline
injections by two-dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI